152 related articles for article (PubMed ID: 8113991)
1. Synthesis and bioactivity of monobiotinylated DALDA: a mu-specific opioid peptide designed for targeted brain delivery.
Bickel U; Yamada S; Pardridge WM
J Pharmacol Exp Ther; 1994 Feb; 268(2):791-6. PubMed ID: 8113991
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the binding of [3H][Dmt1]H-Dmt-D-Arg-Phe-Lys-NH2, a highly potent opioid peptide.
Neilan CL; Janvey AJ; Bolan E; Berezowska I; Nguyen TM; Schiller PW; Pasternak GW
J Pharmacol Exp Ther; 2003 Aug; 306(2):430-6. PubMed ID: 12663687
[TBL] [Abstract][Full Text] [Related]
3. Comparison of [Dmt1]DALDA and DAMGO in binding and G protein activation at mu, delta, and kappa opioid receptors.
Zhao GM; Qian X; Schiller PW; Szeto HH
J Pharmacol Exp Ther; 2003 Dec; 307(3):947-54. PubMed ID: 14534366
[TBL] [Abstract][Full Text] [Related]
4. Stability of the disulfide bond in an avidin-biotin linked chimeric peptide during in vivo transcytosis through brain endothelial cells.
Kang YS; Voigt K; Bickel U
J Drug Target; 2000; 8(6):425-34. PubMed ID: 11328668
[TBL] [Abstract][Full Text] [Related]
5. Antinociceptive and respiratory effects of intrathecal H-Tyr-D-Arg-Phe-Lys-NH2 (DALDA) and [Dmt1] DALDA.
Shimoyama M; Shimoyama N; Zhao GM; Schiller PW; Szeto HH
J Pharmacol Exp Ther; 2001 Apr; 297(1):364-71. PubMed ID: 11259564
[TBL] [Abstract][Full Text] [Related]
6. In vivo pharmacokinetics of selective mu-opioid peptide agonists.
Szeto HH; Lovelace JL; Fridland G; Soong Y; Fasolo J; Wu D; Desiderio DM; Schiller PW
J Pharmacol Exp Ther; 2001 Jul; 298(1):57-61. PubMed ID: 11408525
[TBL] [Abstract][Full Text] [Related]
7. In vivo cleavability of a disulfide-based chimeric opioid peptide in rat brain.
Bickel U; Kang YS; Pardridge WM
Bioconjug Chem; 1995; 6(2):211-8. PubMed ID: 7599264
[TBL] [Abstract][Full Text] [Related]
8. Type and location of fluorescent probes incorporated into the potent mu-opioid peptide [Dmt]DALDA affect potency, receptor selectivity and intrinsic efficacy.
Schiller PW; Berezowska I; Weltrowska G; Chen H; Lemieux C; Chung NN
J Pept Res; 2005 Jun; 65(6):556-63. PubMed ID: 15885115
[TBL] [Abstract][Full Text] [Related]
9. SNF9007: a novel analgesic that acts simultaneously at delta 1, delta 2 and mu opioid receptors.
Williams CL; Rosenfeld GC; Dafny N; Fang SN; Hruby VJ; Bowden G; Cullinan CA; Burks TF
J Pharmacol Exp Ther; 1994 May; 269(2):750-5. PubMed ID: 8182541
[TBL] [Abstract][Full Text] [Related]
10. Characterisation and visualisation of [3H]dermorphin binding to mu opioid receptors in the rat brain. Combined high selectivity and affinity in a natural peptide agonist for the morphine (mu) receptor.
Amiche M; Sagan S; Mor A; Pelaprat D; Rostene W; Delfour A; Nicolas P
Eur J Biochem; 1990 May; 189(3):625-35. PubMed ID: 2161761
[TBL] [Abstract][Full Text] [Related]
11. Potency differences for D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 as an antagonist of peptide and alkaloid micro-agonists in an antinociception assay.
Sterious SN; Walker EA
J Pharmacol Exp Ther; 2003 Jan; 304(1):301-9. PubMed ID: 12490605
[TBL] [Abstract][Full Text] [Related]
12. Central nervous system pharmacologic effect in conscious rats after intravenous injection of a biotinylated vasoactive intestinal peptide analog coupled to a blood-brain barrier drug delivery system.
Wu D; Pardridge WM
J Pharmacol Exp Ther; 1996 Oct; 279(1):77-83. PubMed ID: 8858978
[TBL] [Abstract][Full Text] [Related]
13. Helix-inducing alpha-aminoisobutyric acid in opioid mimetic deltorphin C analogues.
Bryant SD; Guerrini R; Salvadori S; Bianchi C; Tomatis R; Attila M; Lazarus LH
J Med Chem; 1997 Aug; 40(16):2579-87. PubMed ID: 9258365
[TBL] [Abstract][Full Text] [Related]
14. [Dmt(1)]DALDA is highly selective and potent at mu opioid receptors, but is not cross-tolerant with systemic morphine.
Riba P; Ben Y; Nguyen TM; Furst S; Schiller PW; Lee NM
Curr Med Chem; 2002 Jan; 9(1):31-9. PubMed ID: 11860345
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the antinociceptive effects of intrathecal DALDA peptides following bolus intrathecal delivery.
Kokubu S; Eddinger KA; Nguyen TM; Huerta-Esquivel LL; Yamaguchi S; Schiller PW; Yaksh TL
Scand J Pain; 2019 Jan; 19(1):193-206. PubMed ID: 30367811
[TBL] [Abstract][Full Text] [Related]
16. Involvement of endogenous opioid peptides in the antinociception induced by the novel dermorphin tetrapeptide analog amidino-TAPA.
Mizoguchi H; Watanabe C; Watanabe H; Moriyama K; Sato B; Ohwada K; Yonezawa A; Sakurada T; Sakurada S
Eur J Pharmacol; 2007 Apr; 560(2-3):150-9. PubMed ID: 17307162
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological characterization of the dermorphin analog [Dmt(1)]DALDA, a highly potent and selective mu-opioid peptide.
Neilan CL; Nguyen TM; Schiller PW; Pasternak GW
Eur J Pharmacol; 2001 May; 419(1):15-23. PubMed ID: 11348625
[TBL] [Abstract][Full Text] [Related]
18. Dansylated analogues of the opioid peptide [Dmt1]DALDA: in vitro activity profiles and fluorescence parameters.
Berezowska I; Lemieux C; Chung NN; Zelent B; Schiller PW
Acta Biochim Pol; 2004; 51(1):107-13. PubMed ID: 15094830
[TBL] [Abstract][Full Text] [Related]
19. Transcellular transport of a highly polar 3+ net charge opioid tetrapeptide.
Zhao K; Luo G; Zhao GM; Schiller PW; Szeto HH
J Pharmacol Exp Ther; 2003 Jan; 304(1):425-32. PubMed ID: 12490619
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and in vitro opioid activity profiles of DALDA analogues.
Schiller PW; Nguyen TM; Berezowska I; Dupuis S; Weltrowska G; Chung NN; Lemieux C
Eur J Med Chem; 2000 Oct; 35(10):895-901. PubMed ID: 11121615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
